Literature DB >> 33505098

Efficient Editing of an Adenoviral Vector Genome with CRISPR/Cas9.

Qiang Li1,2, Hui Wang1,2, Chen-Yu Gong3, Zhao Chen1,2, Jia-Xing Yang1,2, Hong-Wei Shao1,2, Wen-Feng Zhang1,2.   

Abstract

Immunotherapy based on genetic modification of T cells has played an important role in the treatment of tumors and viral infections. Moreover, adenoviral vectors engineered with improved safety due to their inability to integrate into the host genome have been key in the clinical application of T cell therapy. However, the commonly used adenoviral vector Ad5 exhibits low efficiency of infection of human T cells and the details of the intracellular trafficking pathway of adenoviral vectors in human primary T cells remains unclear. Resolution of these issues will depend on successful modification of the adenoviral vector. To this end, here we describe the successful establishment of a simple and efficient method for editing adenoviral vectors in vitro using the CRISPR-Cas9 gene editing system to target the adenoviral fiber gene. © Association of Microbiologists of India 2020.

Entities:  

Keywords:  Adenoviral vector; CRISPR-Cas9; T-cell therapy

Year:  2020        PMID: 33505098      PMCID: PMC7810804          DOI: 10.1007/s12088-020-00905-3

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  15 in total

1.  A high-efficiency Cre/loxP-based system for construction of adenoviral vectors.

Authors:  P Ng; R J Parks; D T Cummings; C M Evelegh; U Sankar; F L Graham
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

2.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors.

Authors:  Roland Schroers; York Hildebrandt; Justin Hasenkamp; Bertram Glass; André Lieber; Gerald Wulf; Matthias Piesche
Journal:  Exp Hematol       Date:  2004-06       Impact factor: 3.084

Review 4.  Oncolytic herpes simplex virus engineering and preparation.

Authors:  Pankaj K Agarwalla; Manish K Aghi
Journal:  Methods Mol Biol       Date:  2012

5.  Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions.

Authors:  E S Mocarski; L E Post; B Roizman
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

Review 6.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

7.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Authors:  Marco Ruella; Jun Xu; David M Barrett; Joseph A Fraietta; Tyler J Reich; David E Ambrose; Michael Klichinsky; Olga Shestova; Prachi R Patel; Irina Kulikovskaya; Farzana Nazimuddin; Vijay G Bhoj; Elena J Orlando; Terry J Fry; Hans Bitter; Shannon L Maude; Bruce L Levine; Christopher L Nobles; Frederic D Bushman; Regina M Young; John Scholler; Saar I Gill; Carl H June; Stephan A Grupp; Simon F Lacey; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

8.  Adenovirus flow in host cell networks.

Authors:  Justin W Flatt; Sarah J Butcher
Journal:  Open Biol       Date:  2019-02-28       Impact factor: 6.411

9.  Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35.

Authors:  Wen-feng Zhang; Hong-wei Shao; Feng-lin Wu; Xin Xie; Zhu-ming Li; Hua-ben Bo; Han Shen; Teng Wang; Shu-lin Huang
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

Review 10.  Imaging, Tracking and Computational Analyses of Virus Entry and Egress with the Cytoskeleton.

Authors:  I-Hsuan Wang; Christoph J Burckhardt; Artur Yakimovich; Urs F Greber
Journal:  Viruses       Date:  2018-03-31       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.